Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Safety and Tolerability Study of Sotrovimab (VIR-7831) Prophylaxis Against COVID-19 Infection in Immunocompromised Individuals With Impaired SARS-CoV-2 Humoral Immunity

NCT05210101 is registered in ClinicalTrials.gov with Sophia Koo, M.D. as lead sponsor.

NCT NCT05210101
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05210101 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Safety and Tolerability Study of Sotrovimab (VIR-7831) Prophylaxis Against COVID-19 Infection in Immunocompromised Individuals With Impaired SARS-CoV-2 Humoral Immunity
Lead sponsor
Sophia Koo, M.D.
Phase
Phase 2
Overall status
Completed
Start date
February 7, 2022
Completion date
February 28, 2023
Enrollment
93 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

sars cov 2 infection